Carbohydrate-based drugs in the treatment of epilepsy, depression and other affective disorders.
Mental illness affects a quarter of the US population. Recently, it has been shown that new, carbohydrate-based drugs hold promise in the treatment of central nervous system (CNS) disorders. A variety of ways in which drugs of this sort may reduce the symptoms of epilepsy, depression and other affective disorders have been proposed, including: targeting the immune system, disrupting glycolysis, acting at different sites in the hypothalamic-pituitary-adrenal (HPA) axis, and targeting specific biochemical pathways such as the inositol pathway. In the present review, the structure-activity relationships (SARs) of a wide variety of CNS-active carbohydrates are presented.
Talisman
Ian Jamie
IJ
Seton Hall University, Department of Chemistry and Biochemistry, 400 South Orange Ave., South Orange, NJ 07079, USA.
Marzabadi
Cecilia H
CH
D002241:Carbohydrates / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D002490:Central Nervous System / Q000187:drug effects; D002493:Central Nervous System Diseases / Q000188:drug therapy*; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D015394:Molecular Structure; D019964:Mood Disorders / Q000188:drug therapy*; D004364:Pharmaceutical Preparations / Q000737:chemistry; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
D002241:Carbohydrates; D004364:Pharmaceutical Preparations